Ascendis Pharma A (ASND) Interest & Investment Income (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Interest & Investment Income data on file, last reported at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 82.58% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $288.3 million (up 42.58% YoY), and the FY2025 full-year result was $276.3 million, up 171.05% from the prior year.
• Interest & Investment Income fell to $5.3 million in Q1 2026, from $213.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $213.7 million in Q4 2025 to a low of $3.4 million in Q4 2022.
• A 5-year average of $43.6 million and a median of $31.1 million in 2024 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income surged 43363.99% in 2022 and plunged 91.98% in 2024, its largest moves.
• Tracing ASND's Interest & Investment Income over 5 years: stood at $3.4 million in 2022, then jumped by 1090.61% to $40.1 million in 2023, then surged by 119.22% to $88.0 million in 2024, then soared by 142.79% to $213.7 million in 2025, then sank by 97.53% to $5.3 million in 2026.
• Business Quant data shows ASND's Interest & Investment Income at $5.3 million in Q1 2026, $213.7 million in Q4 2025, and $7.1 million in Q3 2025.